Antibodies to the C-terminal fragment of the beta subunit of the insulin receptor (Subetta) – [100 lozenges]

Antibodies to C-terminal fragment of β-subunit sensitize insulin receptor through allosteric modulation mechanisms, increase its sensitivity to both endogenous and injected insulin, which is accompanied by activation of insulin-dependent glucose metabolism.

Antibodies to the β-subunit have been experimentally shown to have a moderately pronounced hypoglycemic effect (decrease in fasting glycemia by 0.7-1.4 mmol/l), while long-term use was not

accompanied by the development of side effects such as hypoglycemia, acidosis, weight gain, hemostasis and hematopoiesis disorders. Antibodies to endothelial NO synthase increase the activity of endothelial NO synthase, which is accompanied by an increase in NO that has endothelium-protective effect, helps to reduce vascular reactivity, decrease vasospasm, normalize blood pressure level and improve peripheral microcirculation.

Antibodies to endothelial NO synthase have a moderately pronounced psychotropic effect in the form of anti-anxiety, anti-asthenic, vegetative and stabilizing effects.

When the components are used together in the Subetta complex preparation, a synergistic effect on the sensitivity of somatic cells to insulin is observed due to a nonspecific NO-dependent activation of intracellular signal transduction from the insulin receptor, which helps to increase the efficiency of insulin therapy, stabilize the doses used and reduce the risk of side effects. The drug reduces the severity of diabetes complications: cardiovascular disorders, neuropathies, nephropathies.

Subetta is indicated for use in adults.

Type 1 diabetes mellitus as an adjunct to basal-bolus insulin therapy.

Type 2 diabetes as part of complex therapy.

Contraindications .

Increased individual sensitivity to the drug components.

Age under 18 years.

Using during pregnancy and lactation.

Pregnancy

No data on the use of Subetta during pregnancy are available.

Breast-feeding period.

No data on penetration of the active substances (metabolites) into human breast milk.